Otsuka Pharmaceutical and Proteus Digital Health re-submitted an FDA application for their chip-in-a-pill, which combines antipsychotic Abilify with an ingestible sensor made by Proteus. The FDA is ...
Proteus Digital Health’ pitch to track adherence using sensor-equipped pills has found another audience in the HIV prevention community. Among the featured data presented at this week’s International ...
REDWOOD CITY, Calif. – July 30, 2012 – Proteus Digital Health, Inc. announced today that the U.S. Food and Drug Administration (FDA) has cleared its ingestible sensor for marketing as a medical device ...
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Proteus Digital Health, Inc. announced today that the U.S. Food and Drug Administration (FDA) has cleared its ingestible sensor for marketing as a medical device ...
Proteus Digital Health has announced it has received FDA clearance for an ingestible sensor, according to a news release. The ingestible sensor, formally referred to as the Ingestion Event Marker, can ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback